Manufacturing:
Over the last eight years, few sectors in the US-China relationship have been transformed as much as manufacturing has. Trade sanctions, tariffs, and the pandemic have all combined to radically alter the manufacturing landscape. In their efforts to mitigate supply-chain disruption, US companies have brought manufacturing back home or shifted it to countries like India, Vietnam, or Thailand. The Chinese government, seeking to focus manufacturing domestically, has enacted a combination of stimulus and regulatory policies, such as the “Made in China 2025” and “Green Manufacturing Upgrade” initiatives, notes Joyce Gong, a senior client partner in the Global Industrial and Consumer Markets practice sought to bolster partnerships with emerging countries and markets outside the US. “Uncertainty, and the need to create jobs, has led both countries to grow domestic manufacturing capabilities,” says Gong.
Given that they are the world’s top two manufacturing leaders—China accounts for about 30 percent of the world’s output, and the US about 16 percent—a complete withdrawal of one country from the other is impossible. “Despite trade and security tensions, China and the US are still highly dependent on each other for manufacturing,” says Kevin Zhang, a professor of economics at Illinois State University who focuses on international trade and the Chinese economy. He cites several possible drivers of collaboration, including the need for both countries to create jobs, as well as possible (if not likely) joint ventures and mergers and acquisitions between US and Chinese companies. Gong agrees, saying that in the medium to long term, “China and the United States may form a pattern of competition and coexistence in manufacturing.” The sectors that could benefit include biotechnology, healthcare and pharmaceuticals, and renewable energy.
Consumer Goods:
Consumer behavior in the US and China differs radically, which presents both challenges and opportunities for consumer companies in both countries. Consumer spending in the US remains robust and confidence in the economy is still high, despite a recent dip. Conversely, even with a spending surge during the Lunar New Year, Chinese consumers have been in saving mode, maintaining a dour outlook on the economy. For instance, a recent Korn Ferry survey showed that 88 percent of consumer-goods CEOs in China are either neutral or pessimistic about the outlook for their sector this year. “The focus in China has been on getting consumers to spend,” says Claudia Wu, leader of Korn Ferry’s Consumer practice in Asia Pacific.
Though US and Chinese consumers are at opposite ends of the spending spectrum, opportunities can be found in the vast ground between them. For instance, though luxury brands declined by 10% to 20% in China in 2024, they grew decently in the US. Chinese consumers spent money on necessities instead of luxury brands, giving fast-moving consumer-goods companies a major boost. Fifty-two percent of fast-moving consumer-goods companies grew revenue last year, according to Korn Ferry’s survey, while 45 percent of traditional retailers saw revenues decline. Illinois State University’s Zhang says rising middle-class wealth rising patriotism in China can also benefit strong brands domestically. For their part, US consumers, particularly 18- to 24-year-olds, are heavily influenced by social media and price point, creating opportunities for Chinese companies—from Lenovo to TikTok to Shein—to gain market share from US counterparts.
Reciprocal tariffs can also benefit consumer-goods companies in their home territories by reducing competition and providing a price-point advantage. Further, Chinese companies can establish manufacturing facilities and autonomous operations in the US, and vice versa, to circumvent tariffs and fuel growth. “This is a real opportunity for consumer-goods leaders to show they can adapt to market uncertainty and master cyclical volatility,” says Wu.
Life Sciences:
Due to the aging population of both countries, life sciences may be the most fruitful sector for US-China collaboration over the next four years. To be sure, earlier this year, the two countries renewed an agreement governing scientific cooperation on research and data sharing in critical areas, like drug development and biotechnology. In particular, potential exists for partnerships and other ventures in healthcare services—in areas such as chronic disease management, biotechnology innovation, medical-device development, and more—says Jonathan Zhu, APAC regional managing partner of the Global Life Sciences practice for Korn Ferry. Industry experts and financial analysts go one step further, predicting cross-border merger-and-acquisition activity between the two countries will pick up in 2025. Recently, for instance, a Chinese life-sciences company sold two manufacturing facilities, one to a US counterpart and another to a US private-equity firm.
Heavy research-and-development costs, strict regulations, and differences between the Chinese and American healthcare systems also open avenues for life-sciences companies in both countries to work together to share costs, navigate policies, and deliver care, say experts. Or, as Zhu says, “Life-sciences companies in the US and China are more aware of each other’s markets, and know that they need local organizational support, local relationships, and local talent to drive growth.”
For more information, contact Audrey Tan at audrey.tan@kornferry.com;Tao Li at tao.li@kornferry.com; Norman Zhou at norman.zhou@kornferry.com; Joyce Gong at joyce.gong@kornferry.com; Claudia Wu at claudia.wu@kornferry.com; or Jonathan Zhu at jonathan.zhu@kornferry.com.